Nasdaq · CIK 0000771856
CSBR CHAMPIONS ONCOLOGY, INC.
Insider trading from SEC Form 4. Last filing Apr 2, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
5
with a Form 4 at this company
Signals
Open-market buys and sells at CHAMPIONS ONCOLOGY, INC., scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
The last 10 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 25, 2025 | Philip P. Breitfeld director | JOther Common Stock | -4,150 | $0.00 | $0 | 5,717 | Apr 2, 2025 |
| Nov 12, 2024 | Joel Ackerman director | AGrant or award Option to purchase Common Stockderivative | +43,190 | $4.64 | $200k | 43,190 | Nov 18, 2024 |
| Nov 12, 2024 | Philip P. Breitfeld director | AGrant or award Option to purchase Common Stockderivative | +18,715 | $4.64 | $87k | 18,715 | Nov 18, 2024 |
| Nov 12, 2024 | Scott R Tobin director, owner | AGrant or award Option to purchase Common Stockderivative | +34,550 | $4.64 | $160k | 34,550 | Nov 18, 2024 |
| Nov 12, 2024 | Daniel Newman Mendelson director | AGrant or award Option to purchase Common Stockderivative | +21,590 | $4.64 | $100k | 21,590 | Nov 18, 2024 |
| Nov 12, 2024 | David Sidransky director | AGrant or award Option to purchase Common Stockderivative | +21,880 | $4.64 | $102k | 21,880 | Nov 18, 2024 |
| Oct 31, 2024 | Joel Ackerman director | MOption exercise Common Stock | +88,470 | $2.10 | $186k | 945,467 | Nov 1, 2024 |
| Oct 31, 2024 | Joel Ackerman director | MOption exercise Common Stock | +16,667 | $5.43 | $91k | 962,134 | Nov 1, 2024 |
| Oct 31, 2024 | Joel Ackerman director | MOption exercise Option to purchase Common Stockderivative | -88,470 | $2.10 | $186k | 0 | Nov 1, 2024 |
| Oct 31, 2024 | Joel Ackerman director | MOption exercise Option to purchase Common Stockderivative | -16,667 | $5.43 | $91k | 0 | Nov 1, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Joel Ackermandirector, cfo, officer
- Philip P. Breitfelddirector
- Daniel Newman Mendelsondirector
- David Sidranskydirector
- Scott R Tobindirector, owner
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.